Drug Trial Radar · NCT06958861
A Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Inhaled H057 in the Treatment of Acute Exacerbations of Bronchiectasis
Last checked: Nov 20, 2026Latest source record: May 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
180
Planned (sponsor's estimate)
Start
May 2025
Primary completion
May 2027
Study completion May 2027
Sponsor
- Lead sponsor
- Shanghai Huilun Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 6, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of inhaled H057 in the treatment of acute exacerbations of bronchiectasis.
Conditions
- Acute Exacerbations of Bronchiectasis
Interventions
Low-dose H057+standard-of-careDrug
Subjects are administered low-dose inhaled H057, combined with standard-of-care treatment, which included anti-infective therapy, expectorant therapy, hemostasis, oxygen therapy, and other supportive measures.
High-dose H057+standard-of-careDrug
Subjects are administered high-dose inhaled H057, combined with standard-of-care treatment, which included anti-infective therapy, expectorant therapy, hemostasis, oxygen therapy, and other supportive measures.
H057 placebo+standard-of-careDrug
Subjects are administered inhaled H057 placebo, combined with standard-of-care treatment, which included anti-infective therapy, expectorant therapy, hemostasis, oxygen therapy, and other supportive measures.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Quality-of-Life Bronchiectasis Respiratory Symptom ScoreTime frame: baseline to day 15
Locations
19 sites in 1 country. Site status is shown where the registry gives one.
Fuyang Hospital Of Anhui Medical University
Fuyang, Anhui, China
Hefei First People's Hospital
Hefei, Anhui, China
Fujian Medical University Union Hospital
Fuzhou, Fujian, China
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
Peking University Shenzhen Hospital
Shenzhen, Guangdong, China
Affiliated hospital of Youjiang Medical University For Nationalities
Baise City, Guangxi, China
Hebei General Hospital
Shijiazhuang, Hebei, China
Nanyang Second General Hospital
Nanyang, Henan, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Yichang Central People's Hospital
Yichang, Hubei, China
The second Xiangya Hospital of Central South University
Changsha, Hunan, China
Changzhou First People's Hospital
Changzhou, Jiangsu, China
Jiujiang No.1 People's Hospital
Jiujiang, Jiangxi, China
Sichuan Provincial People's Hospital
Chengdu, Sichuan, China
Deyang People's Hospital
Deyang, Sichuan, China
Hangzhou First People's Hospital
Hangzhou, Zhejiang, China
Jinhua Municipal Central Hospital
Jinhua, Zhejiang, China
Ningbo No.2 Hospital
Ningbo, Zhejiang, China
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.